Hong Kong Stock Afternoon Review|Hang Seng Index fell 0.53% in early trading Hang Seng Biotech Index fell 2.73%

The Zhitong Finance App learned that the Hong Kong stock Hang Seng Index fell 0.53% to 128 points to 24,151 points; the Hang Seng Technology Index fell 0.91%. Hong Kong stocks traded HK$51.7 billion in early trading.

Allis vormetinib lost the third phase of the global phase, and the US stock ArriVent stock price plummeted, triggering an overall correction in the Hong Kong pharmaceutical sector. The Hang Seng Biotech Index fell 2.73%; the Hang Seng Innovative Drugs Index fell 2.21%. Kingsley Biotech (01548) fell more than 13%, and Zhaoyan New Pharmaceutical (06127) fell more than 7%.

Benmao Technology (06731) increased by more than 5%, and joined hands with China Science and Technology Innovation to promote deep coupling between new rare earth materials and the robot industry.

Rebang Pharmaceutical-B (09637) rose 6%. Agencies say AP308 is expected to unlock a broader IgA nephropathy market.

Weichai Power (02338) rose more than 5%, and the AIDC business is expected to drive mid-term performance growth and valuation increase.

CGN Mining (01164) rose more than 5%, and Google and Constellation Energy reached an agreement to install 890 megawatts of nuclear power.

Daikin Heavy Industries (01081) rose more than 5%, increasing the visibility of future order recovery in the European Seabreeze supply chain.

Quanfeng Holdings (02285) rose more than 4%, and major senior personnel arrangements were implemented one after another. Daiwa is optimistic about the company's new executive team.

AI hardware stocks had the highest declines. Cloud vendors have run out of cash flow, and the market is concerned about the continuity of subsequent capital expenditure support. Zhaoyi Innovation (03986) fell 3%; Lanqi Technology (06809) fell 6%.